Correlation of Ultrasound-Measured Detrusor and Bladder Wall Thickness With Urodynamic Parameters in Spinal Cord Injury

February 16, 2026 updated by: Ankara City Hospital Bilkent

Correlation of Suprapubic Ultrasound-Measured Detrusor and Bladder Wall Thickness With Urodynamic Parameters in Patients With Spinal Cord Injury

This study aims to investigate the correlation between detrusor and bladder wall thickness measured by suprapubic ultrasound and urodynamic parameters in patients with spinal cord injury. By evaluating ultrasonographic measurements alongside urodynamic findings, the study seeks to assess their relationship in a prospective cross-sectional setting.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Detailed Description

This single-center, prospective cross-sectional observational study was conducted to evaluate the association between detrusor and bladder wall thickness measured by suprapubic ultrasound and urodynamic parameters in patients with spinal cord injury. Patients with spinal cord injury were prospectively enrolled and underwent suprapubic ultrasonography and urodynamic evaluation as part of the study protocol.

Detrusor wall thickness and bladder wall thickness were measured using suprapubic ultrasonography according to a standardized protocol. Urodynamic parameters, including detrusor pressure and other relevant measurements, were recorded during routine urodynamic assessment. The relationship between ultrasonographic measurements and urodynamic findings was analyzed to assess their correlation.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
116

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey (Türkiye)
    • Çankaya
      • Ankara, Çankaya, Turkey (Türkiye), 06800
        • Ankara Bilkent City Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients with spinal cord injury admitted to the inpatient rehabilitation program at Ankara Bilkent City Hospital Physical Therapy and Rehabilitation Hospital, referred to the Urodynamy Laboratory, who met the inclusion criteria and consented to participate in the study.

Description

Inclusion Criteria:

  1. ≥18-65 years of age
  2. Traumatic and non-traumatic SCI
  3. Willingness to participate and able to provide written informed consent

Exclusion Criteria:

  1. Neurogenic lower urinary tract dysfunction not caused by spinal cord injury
  2. History of brain surgery
  3. History of augmentative urinary surgery or invasive bladder procedures (e.g., bladder tumor resection, botulinum toxin injection)
  4. History of urinary tract malignancy
  5. Prior overactive bladder or urinary incontinence, or prior surgery for benign prostatic hyperplasia
  6. Bladder outlet obstruction
  7. Cognitive impairment that would interfere with participation
  8. Active urinary tract infection preventing urodynamic evaluation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Correlation between ultrasound-measured detrusor and bladder wall thickness and urodynamic parameters
Time Frame: Ultrasonographic measurements were performed during the same clinical evaluation period, either on the same day as or within one day prior to the urodynamic study.
The association between suprapubic ultrasound-measured bladder wall thickness and detrusor wall thickness and urodynamic parameters, including cystometric capacity, maximum cystometric capacity, maximum detrusor pressure, leak point pressure, bladder capacity at the time of leakage, total leakage volume, bladder compliance, presence of bladder sensation, presence of detrusor overactivity, presence of sphincter hyperactivity, maximum flow rate, detrusor pressure at maximum flow, voided volume, and postvoid residual urine volume.
Ultrasonographic measurements were performed during the same clinical evaluation period, either on the same day as or within one day prior to the urodynamic study.

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Association of bladder and detrusor wall thickness with clinical characteristics
Time Frame: During the same clinical evaluation period as the urodynamic study, either on the same day as or one day prior to urodynamic testing.
The association between suprapubic ultrasound-measured bladder wall thickness and detrusor wall thickness (measured in millimeters, mm) and clinical characteristics, including sex (male/female), neurological level of injury, distribution of paralysis (paraplegia/tetraplegia), injury severity according to the ASIA Impairment Scale (AIS A-E), duration since injury (months), etiology of spinal cord injury, bladder emptying method, use of anticholinergic medication (yes/no), presence of pressure ulcers (yes/no), and history of recurrent urinary tract infections (yes/no).
During the same clinical evaluation period as the urodynamic study, either on the same day as or one day prior to urodynamic testing.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Ankara City Hospital Bilkent

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Hakan Tunç, Professor doctor, Ankara City Hospital Bilkent

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
February 21, 2024

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
October 1, 2025

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
October 1, 2025

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
January 19, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
February 16, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
February 18, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
February 18, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
February 16, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
January 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 2-24-12

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings